Just a short time ago, President Trump announced a new change on cannabis policy. In an executive order signed this afternoon, the president laid out his intention to reclassify cannabis under the Controlled Substances Act. Right now, cannabis is a schedule one substance along with drugs like heroin, LSD.Under the law, these drugs are considered to have the highest potential for abuse and no medical use. Under the executive order, cannabis would now become a schedule three substance, falling into the same c ...

All right, so we're coming off last week, two weeks of gains and a lot of it was that PC on Friday at least that kind of kept us going. Y the fact that inflation came in just a tick lower giving people confident about the Fed rate cut. What areas of the market does that make you bullish on.>> So a lot of what I've been talking about for a while is focusing on down on the market cap spectrum. So look at those small and mids and these are exactly the companies that are going to benefit the most for this kind ...

RT Charles Gorrivan (@CGorrivan)Two GOP lawmakers were invited to an FDA approval meeting involving Patrick Soon-Shiong’s Anktiva, an unusual step for an agency meant to stay apolitical. Officials “forcefully” objected and the plan was dropped. Scoop w/ @rachelcohrs and @gerryfsmith. https://t.co/fO90P6PRPI ...

RT Thomas Brewster (@iblametom)🚨NEW🚨 A couple made millions from an anti-choking device that sucked objects out of throats, claiming it was FDA-approved.But the FDA had told them to stop selling it.Meanwhile, similar devices were on Amazon up until this week when I flagged them.https://t.co/3yuenho1sV ...

Company Overview - Kura Oncology is preparing for the FDA approval of ziftomenib, with a PDUFA date set for November 30, indicating confidence in obtaining a competitive label for relapsed/refractory NPM1-mutant AML [3]. Product Development - The company has received positive feedback from key opinion leaders (KOLs) regarding the efficacy, simplicity, compatibility, and safety of ziftomenib compared to competitors [3]. - Kura's commercial team is fully established and ready for market access and preapproval information exchanges [3]. Future Prospects - Kura Oncology is also advancing ziftomenib in combination with standard treatments for frontline indications, indicating a strategic focus on expanding its therapeutic applications [4].

Technology & Procedure - Hystotripsy, utilizing targeted ultrasound waves, offers a non-invasive method for tumor destruction [2] - The Edison system by HystoSonics is currently the only commercially available hystotripsy machine for human use [2] - Hystotripsy mechanically destroys tumor cells by rapidly expanding and contracting gases within them, liquefying the tissue instantly [7] - The procedure typically takes 1 to 3 hours, depending on the number of tumors targeted [18] Clinical Trials & Applications - Hystotripsy received FDA approval in October 2023 and is expanding availability [20] - While primarily focused on liver tumors, hystotripsy has potential applications for tumors in other organs [13] - Trials are underway for kidney and pancreatic tumors, with US availability for pancreatic tumor treatment expected in 2026 [15][16] - Future trials may explore applications for prostate (BPH and cancer), uterine fibroids, breast tumors, thyroid nodules, and even brain tumors [17] Post-Procedure & Immune Response - Most patients can return home a few hours after the procedure [19] - The body's immune system naturally absorbs the liquefied tumor [11] - Animal studies suggest hystotripsy may offer a systemic immunologic benefit by exposing hidden tumor antigens to the immune system [11][12]

Core Insights - Arquitos Capital Management reported a net return of 13.1% for Q2 2025, with year-to-date gains reaching 28.8% as of June 30, 2025 [1] Company Overview - Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company focused on developing, manufacturing, and commercializing products for unmet patient needs in the U.S. [2] - As of September 22, 2025, Liquidia's shares closed at $22.90, with a market capitalization of $1.922 billion [2] Stock Performance - Liquidia's stock experienced a decline of 19.40% over the past month, but it gained 120.85% over the last 12 months [2] - Following the FDA approval and launch of its flagship drug Yutrepia, Liquidia's stock price fell from over $19 in early June to $12.46 by the end of Q2 2025, attributed to investor concerns regarding the commercial rollout and potential competition [3] Product Launch and Market Position - The launch of Yutrepia is critical for Liquidia, as it aims to penetrate a previously monopolistic market [3] - Despite challenges such as patent disputes and FDA approval delays, Liquidia's shares have increased by 200% compared to the original purchase price over three years [3]

Clinical Trial Results & FDA Approval - Lilly's oral pill data for obesity and Type 2 diabetes initially caused significant market disappointment [1][2] - The recent data is viewed as the final step before submitting plans to the FDA for approval of the pill [2] - FDA approval is anticipated no earlier than 2026 [4] Market Expectations & Potential - Long-term expectations for the pill have decreased due to weight loss percentage and gastrointestinal side effects [3] - Despite lowered expectations, the pill is still projected to become a multi-billion dollar product in the US market [3] Side Effects & Advantages - The pill's side effects include diarrhea, nausea, and gastrointestinal issues, comparable to other medications like Wegovy [5] - The primary advantage of the pill is its convenience as a once-daily oral medication compared to weekly injections [6]

What if dogs could live longer? Celine Halioua has raised $135 million from top investors to develop canine longevity pills—and expects to get her first conditional approval from the FDA next year. https://t.co/XPMe2lfUUh (Photo: Ethan Pines For Forbes) #BillionDollarStartups https://t.co/QMtkigu7m7 ...

Core Insights - InspireMD, Inc. has made significant progress in 2024, particularly with the CGuard Prime carotid stent system, which is on track for potential U.S. approval in the first half of 2025 [3][10] - The company reported a revenue increase of 10.7% in Q4 2024 compared to Q4 2023, driven by growth in both new and existing markets [4][11] - Despite revenue growth, gross profit decreased due to rising costs, leading to a net loss of $9.17 million in Q4 2024, compared to a net loss of $5.41 million in Q4 2023 [5][7][16] Recent Business Highlights - The CEO highlighted the advancement of CGuard Prime towards FDA approval and the initiation of the CGUARDIANS II pivotal study for the TCAR market [3][10] - The company established its headquarters in Miami, Florida, to support the anticipated U.S. commercial launch of CGuard Prime [10] Financial Results for Q4 2024 - Total revenue for Q4 2024 was $1.95 million, up from $1.76 million in Q4 2023 [4][23] - Gross profit for Q4 2024 was $469,000, down from $505,000 in Q4 2023, reflecting increased costs of goods sold [5][23] - Operating expenses rose to $9.84 million in Q4 2024, a 55.8% increase from $6.31 million in Q4 2023, primarily due to higher salaries and clinical expenses [6][23] Financial Results for Full Year 2024 - For the full year 2024, revenue increased by 13.0% to $7.01 million from $6.21 million in 2023 [11][23] - Gross profit for the full year decreased by 16.7% to $1.51 million, with a gross margin decline to 21.5% from 29.1% in 2023 [12][13][23] - The net loss for the full year totaled $32.01 million, compared to a net loss of $19.92 million in 2023 [16][23] Cash Position - As of December 31, 2024, cash and cash equivalents and marketable securities totaled $34.64 million, down from $39.02 million a year earlier [8][23]